About Affymetrix

Stock Quote

Security
AFFX (Common Stock)
$10.22
-1.54%
Current Day's High
10.49
Current Day's Low
9.99
Current Day's Volume
1,124,356
Last Trade
Jul 06 15 4:00 p.m. ET
Exchange
NASDAQ

The stock price performance shown on the quote above is not necessarily indicative of future price performance

Investors

Webcast ImageQ2 2015 Affymetrix Earnings Conference Call
07/29/15 at 5:00 p.m. ET
Webcast -
 Live
Q2 2015 Affymetrix Earnings Conference Call
Wednesday, July 29, 2015 5:00 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Investor Relations Contact

Doug Farrell
VP Investor Relations & Treasury
Tel. 408-731-5285
Fax. 408-731-5750
investor@affymetrix.com

Investor Kit

Download Documentation2014 Annual Report
Download Documentation2015 Proxy

Recent News

TitleDate
Affymetrix to Report Second Quarter 2015 Operating Results on Wednesday July 29, 2015
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jul. 6, 2015-- Affymetrix, Inc. (NASDAQ:AFFX) today announced that it will report operating results for the second quarter of 2015 after market close on Wednesday July 29, 2015. The company will hold a conference call on the same day at 5:00pm ET. A live webcast can be accessed by visiting the Investor Relations section of the company’s website at www.affymetrix.com. Alternatively, investors and other ... 
07/06/15
Affymetrix Appoints Riccardo Pigliucci to Board of Directors
SANTA CLARA, Calif.--(BUSINESS WIRE)--May 18, 2015-- Affymetrix (NASDAQ: AFFX) today announced that Riccardo Pigliucci has been appointed to the company’s board of directors effective May 13, 2015. Mr. Pigliucci will serve as a member of the Compensation Committee. Mr. Pigliucci has served as the Managing Partner of Aldwych Associates, LLP, a management and technology consulting partnership since 2006. Prior to joining Aldwych Associates, ... 
05/18/15
Affymetrix Acquires Assets of Eureka Genomics Corporation to Provide High Throughput and Economical Crop and Animal Genotyping
SANTA CLARA, Calif.--(BUSINESS WIRE)--May 14, 2015-- Affymetrix, Inc., (NASDAQ:AFFX) announced today that it has acquired substantially all the assets of Hercules, CA-based Eureka Genomics® Corporation for $15 million in an all cash transaction. Eureka Genomics is a developer of cost-effective, low- to mid-plex, high throughput genotyping assays that use common next-generation sequencing (NGS) platforms for signal readout. These assays enab... 
05/14/15
Affymetrix Reports First Quarter 2015 Operating Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr. 29, 2015-- Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the first quarter of 2015. Results for the three months ended March 31, 2015: Reported revenue growth of 6.9% and 9.1% on a constant currency basis. Total revenue was $88.7 million, compared to $83.0 million in first quarter of 2014. Product revenue was $79.4 ... 
04/29/15
Affymetrix and EverGene Ltd., a Subsidiary of MTI Ltd., Collaborate in Genetic Research and Personal Genomics Services in Japan
SANTA CLARA, Calif. & TOKYO--(BUSINESS WIRE)--Apr. 13, 2015-- Affymetrix (NASDAQ:AFFX) and MTI Ltd. (TSE:9438), through its wholly-owned subsidiary, EverGene Ltd., (MTI/EG) announce that the two companies will collaborate in genetic research and personal genomics services in Japan. With the support of leading academics and through this collaboration, MTI/EG plans to further expand their business in the healthcare field. MTI/EG, a perso... 
04/13/15
Affymetrix to Report First Quarter 2015 Operating Results on Wednesday April 29, 2015
SANTA CLARA, Calif.--(BUSINESS WIRE)--Apr. 6, 2015-- Affymetrix, Inc. (NASDAQ: AFFX) today announced that it will report operating results for the first quarter of 2015 after market close on Wednesday April 29, 2015. The company will hold a conference call on the same day at 5:00pm ET. A live webcast can be accessed by visiting the Investor Relations section of the company’s website at www.affymetrix.com. Alternatively, investors and other... 
04/06/15
Affymetrix to Webcast Presentation at the 2015 Leerink Global Healthcare Conference
SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb. 6, 2015-- Affymetrix, Inc. (Nasdaq:AFFX) today announced that it will webcast the Company’s presentation at the Leerink Global Healthcare Conference in New York City on Wednesday February 11, 2015. The live webcast is scheduled to begin at 10:15 a.m. ET and will feature a corporate update by Frank Witney, president and chief executive officer. A live webcast will be available at http://www.affymetrix.com... 
02/06/15
Affymetrix Reports Fourth Quarter and Fiscal Year 2014 Results
SANTA CLARA, Calif.--(BUSINESS WIRE)--Feb. 4, 2015-- Affymetrix, Inc. (NASDAQ:AFFX) today reported its operating results for the three and twelve months ended December 31, 2014. Results for the year ended December 31, 2014: Total revenue was $349.0 million, as compared to total revenue of $330.4 million in 2013. Total revenue grew by 8.9% in 2014, after adjusting for a one-time license payment of $5.3 million in 2013 and ... 
02/04/15
Affymetrix Chairman and Founder to Retire from Board of Directors
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 30, 2015-- Affymetrix (NASDAQ:AFFX) today announced that Founder and Chairman, Stephen Fodor, Ph.D., will retire from the company’s Board of Directors effective January 30, 2015. He has served on the Board since the Company’s inception, and has been Chairman since 1999. The Board of Directors elected Jami Nachtsheim as Chairwoman of the Company’s Board of Directors, succeeding Dr. Fodor. Ms. Nachtsheim ha... 
01/30/15
Affymetrix to Report Fourth Quarter and Fiscal Year 2014 Operating Results on Wednesday February 4, 2015
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 22, 2015-- Affymetrix, Inc. (NASDAQ:AFFX) today announced that it will report operating results for the fourth quarter and fiscal year 2014 after market close on Wednesday February 4, 2015. The company will hold a conference call on the same day at 5:00pm ET. A live webcast can be accessed by visiting the Investor Relations section of the company’s website at www.affymetrix.com. Alternatively, inv... 
01/22/15
— Affymetrix Announces Preliminary Fourth Quarter 2014 Revenue of Approximately $93 Million and the Appointment of Merilee Raines to the Board of Directors —
SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 12, 2015-- Affymetrix, Inc., (NASDAQ:AFFX) today announced that based on preliminary, unaudited financial data, the Company expects total revenue for the fourth quarter of 2014 to be approximately $93 million. For fiscal 2014, the Company expects total revenue of approximately $348 million, representing a 9% growth over the prior year, after adjusting for the sale of its Anatrace business with revenues of $4.5 m... 
01/12/15
Affymetrix Expands Portfolio of Axiom Genotyping Arrays For Agrigenomics with New Offerings for Porcine and Equine Studies
PAG XXIII January 10 – 14, 2015 Affymetrix Booth #319 SANTA CLARA, Calif.--(BUSINESS WIRE)--Jan. 11, 2015-- Affymetrix, Inc. (NASDAQ: AFFX) will be highlighting several new genotyping arrays at the 2015 Plant and Animal Genome Conference (PAGXXIII) for applications in breeding and routine analysis. Affymetrix now offers the largest catalog of arrays for research and applied agriculture markets. The newest arrays, Axiom... 
01/11/15
eBioscience, an Affymetrix Business, Launches the First Assay to Detect RNA and Protein Simultaneously in Millions of Single Cells
SANTA CLARA, Calif.--(BUSINESS WIRE)--Dec. 9, 2014-- eBioscience, an Affymetrix (Nasdaq:AFFX) business, announces the availability of PrimeFlow™ RNA Assay, the first and only flow cytometry assay capable of simultaneous detection of RNA and protein within millions of cells at single-cell resolution. Current flow cytometry applications are limited to antibody-based interrogation of cell surface and intracellular proteins. With the novel Prim... 
12/09/14
The Binding Site and eBioscience, an Affymetrix Business, Partner in Clinical Flow Cytometry Reagent Agreement
SANTA CLARA, Calif.--(BUSINESS WIRE)--Dec. 3, 2014-- Affymetrix (NASDAQ:AFFX) announces that eBioscience, an Affymetrix business, and Binding Site Group Ltd. have entered into a multi-year distribution agreement. Under this agreement, The Binding Site has been granted the exclusive rights to distribute the eBioscience clinical flow cytometry reagents (ASR & CE marked) in the clinical care market, including hospitals and reference labs. ... 
12/03/14
Toshiba Corporation Selects Affymetrix Axiom Platform for Its Newly Launched Genotyping Service in Japan
SANTA CLARA, Calif.--(BUSINESS WIRE)--Dec. 1, 2014-- Affymetrix (NASDAQ: AFFX) announces its Axiom® Genotyping Solution platform has been selected by Toshiba Corporation’s (TYO: 6502) Healthcare Company as the platform for its newly launched genotyping service. Affymetrix collaborated with Toshiba to custom design and manufacture the Japonica Array™, which is based on the Axiom platform. This array contains unique genetic content specifical... 
12/01/14

Receive Email Alerts

Sign up to receive e-mail alerts whenever Affymetrix posts new information to the site. Just enter your e-mail address and click Submit.


Data provided by Nasdaq. Minimum 15 minutes delayed.

Back to Top >